EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting the DNA damage response for cancer therapy

Nicola J Curtin iD

Biochemical Society Transactions · 27.02.2023 · 51 (1) · 207-221

DOI: 10.1042/bst20220681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Society Transactions, online erschienen am 06.01.2023. Verfasst von Nicola J Curtin. Beteiligte Einrichtung: Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle u…. Hauptthemen laut MEDLINE: DNA Damage, Neoplasms. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DNA damage response (DDR) is an elegant system, coordinating DNA repair with cell cycle checkpoints, that evolved to protect living organisms from the otherwise fatal levels of DNA damage inflicted by endogenous and environmental sources. Since many agents used to treat cancer; radiotherapy and cytotoxic chemotherapy, work by damaging DNA the DDR represents a mechanism of resistance. The original rational for the development of drugs to inhibit the DDR was to overcome this mechanism of resistance but clinical studies using this approach have not led to improvements in the therapeutic index. A more exciting approach is to exploit cancer-specific defects in the DDR, that represent vulnerabilities in the tumour and an opportunity to selectively target the tumour. PARP inhibitors (PARPi) selectively kill homologous recombination repair defective (HRD, e.g. through BRCA mutation) cells. This approach has proven successful clinically and there are now six PARPi approved for cancer therapy. Drugs targeting other aspects of the DDR are under pre-clinical and clinical evaluation as monotherapy agents and in combination studies. For this promising approach to cancer therapy to be fully realised reliable biomarkers are needed to identify tumours with the exploitable defect for monotherapy applications. The possibility that some combinations may result in toxicity to normal tissues also needs to be considered. A brief overview of the DDR, the development of inhibitors targeting the DDR and the current clinical status of such drugs is described here.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA DamageNeoplasmsHumansDNA RepairPoly(ADP-ribose) Polymerase InhibitorsBiomarkers

Stichwörter der Autor:innen

ATMATRCHK1DNA damage responseDNA-PKPARP

Substanzen

Poly(ADP-ribose) Polymerase InhibitorsBiomarkers

Autor:innen und Institutionen

  • Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, U.K.

ORCID-Profile: Nicola J Curtin

Zitieren

APA

Curtin, N. J. (2023). Targeting the DNA damage response for cancer therapy. Biochemical Society Transactions, 51(1), 207-221. https://doi.org/10.1042/bst20220681

Vancouver

Curtin NJ. Targeting the DNA damage response for cancer therapy. Biochemical Society Transactions. 2023;51(1):207-221. doi:10.1042/bst20220681

BibTeX
@article{Curtin2023,
  author = {Curtin, Nicola J},
  title = {Targeting the DNA damage response for cancer therapy},
  journal = {Biochemical Society Transactions},
  year = {2023},
  volume = {51},
  number = {1},
  pages = {207--221},
  doi = {10.1042/bst20220681}
}
Kostenlos starten →